Citations

Clear

6273 citation(s) found for "To, Andrew".

Abstract 2752: Genetic heterogeneity of ovarian cancer survival effects in BRCA1/2 germline mutations: a large, multi-center study
Goh, Cindy, Goldgar, David E., Easton, Douglas F. , Peock, Susan, Investigators, kConFab, Goode, Ellen L. , Greene, Mark H. , Loud, Jennifer T. , Mai, Phuong , Gore, Martin, Moysich, Kirsten, Beattie, Mary, Sucheston, Lara, Despierre, Evelyn, Gross, Jenny , Walsh, Christine M. , Antoniou, Antonis C. , Bolton, Kelly L. , Ramus, Susan J. , Benı́tez, Javier , Osório, Ana , Godwin, Andrew K. , Kwong, Ava , Blanco, Ignacio , Investigators, kConFab, Toland, Amanda Ewart , Olsson, Håkan , Neuhausen, Susan L. , Montagna, Marco , Lambrechts, Diether , Karlan, Beth Y. , Chenevix‐Trench, Georgia , Pharoah, Paul D.P.

Mayo Clinic

Cancer Research | June 27, 2012 | Volume: 71 | Issue: 8_Supplement | Pages: 2752-2752

10.1158/1538-7445.am2011-2752 Get It

Abstract Rare germline mutations in the breast and ovarian cancer predisposition genes BRCA1 and BRCA2 are present in roughly 5 percent of ovarian cancer patients. Both genes play key roles in DNA damage repair but appear to have distinct, although often complementary, functions. The risks of breast and ovarian cancer have been shown to differ between BRCA1 and BRCA2 carriers, and mutation-specific effects have also been suggested for both groups. Published reports comparing the survival of ovarian cancer patients with and without BRCA1/2 mutations generally show a survival advantage among mutation carriers. This is thought to be related to an improved response of carriers to platinum-based therapies. Since it is not known whether BRCA1 and BRCA2 carriers show similar survival patterns, we have performed a large, multicenter study to investigate the impact of germline BRCA1 and BRCA2 mutations on ovarian cancer survival. 3,531 invasive epithelial ovarian cancer cases (1,178 BRCA1, 367 BRCA2 and 1,986 BRCA-negative) with survival time data from twenty-four studies in the U.S.A, Europe, Israel and Asia were included. In our main analysis, we excluded patients who were known or who were likely to have not received platinum-based therapy. Compared to non-carriers, BRCA1 and BRCA2 carriers were more likely to present with advanced stage (BRCA1; p=2×10−4, BRCA2; p=4×10−6), high grade (BRCA1; p=4×10−9, BRCA2; p=1×10−4), serous disease (BRCA1; p=3×10−6, BRCA2; p=0.003). BRCA1 carriers were younger at diagnosis (p=2×10−9) and BRCA2 slightly older at diagnosis (p=0.002) than non-carriers. BRCA1 and BRCA2 carriers did not differ in terms of tumor stage, grade or histology but did show differences in the age at diagnosis (p=2×10−14). In an unadjusted analysis, neither BRCA1 nor BRCA2 carriers differed from non-carriers in overall survival (BRCA1: HR=1.02, p=0.77, BRCA2: HR=0.89, p=0.36). After adjusting for stage, grade, histology and age at diagnosis, BRCA1 carriers showed a modest, non-significant, survival advantage (HR=0.84, p=0.12) while BRCA2 carriers showed a marked improvement (HR=0.57, p=6×10−4) compared to non-carriers. This survival advantage was also seen when comparing BRCA2 carriers to BRCA1 carriers after adjustment for age at diagnosis (HR=0.69, p=5×10−4). Similar results were obtained when we restricted the analysis to high grade, advanced stage, serous cases. The survival differences we observed between BRCA1 and BRCA2 carriers could be related to differences in tumor biology or chemo-sensitivity. Additional analyses investigating the later will be presented in addition to mutation-specific effects within BRCA1 and BRCA2. In this study, we provide strong evidence for genetic heterogeneity of survival effects in ovarian cancer patients with BRCA mutations. This could be applied to both clinical prediction and to aid our understanding of the complex biology of BRCA mutations. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 2752. doi:10.1158/1538-7445.AM2011-2752
Treatment-influenced associations of PML-RARα mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia
Gallagher, Robert E. , Moser, Barry Kurt, Racevskis, Janis, Bloomfield, Clara D. , Carroll, Andrew J. , Ketterling, Rhett P. , Roulston, Diane, Schachter-Tokarz, Esther, Zhou, Da-Cheng, Chen, I-Ming L., Harvey, Richard C. , Koval, Greg, Sher, Dorie A., Feusner, James H., Tallman, Martin S. , Larson, Richard A. , Powell, Bayard L., Appelbaum, Frederick R. , Paietta, Elisabeth , Poiré, Xavier , Willman, Cheryl L. , Stock, Wendy , Harvey, Richard , Larson, Richard A , Ketterling, Rhett P

Mayo Clinic

Blood | June 27, 2012 | Volume: 120 | Issue: 10 | Pages: 2098-2108

10.1182/blood-2012-01-407601 | PMID 22734072 Get It

AbstractMutations in the all-trans retinoic acid (ATRA)–targeted ligand binding domain of PML-RARα (PRα/LBD+) have been implicated in the passive selection of ATRA-resistant acute promyelocytic leukemia clones leading to disease relapse. Among 45 relapse patients from the ATRA/chemotherapy arm of intergroup protocol C9710, 18 patients harbored PRα/LBD+ (40%), 7 of whom (39%) relapsed Off-ATRA selection pressure, suggesting a possible active role of PRα/LBD+. Of 41 relapse patients coanalyzed, 15 (37%) had FMS-related tyrosine kinase 3 internal tandem duplication mutations (FLT3-ITD+), which were differentially associated with PRα/LBD+ depending on ATRA treatment status at relapse: positively, On-ATRA; negatively, Off-ATRA. Thirteen of 21 patients (62%) had additional chromosome abnormalities (ACAs); all coanalyzed PRα/LBD mutant patients who relapsed off-ATRA (n = 5) had associated ACA. After relapse Off-ATRA, ACA and FLT3-ITD+ were negatively associated and were oppositely associated with presenting white blood count and PML-RARα type: ACA, low, L-isoform; FLT3-ITD+, high, S-isoform. These exploratory results suggest that differing PRα/LBD+ activities may interact with FLT3-ITD+ or ACA, that FLT3-ITD+ and ACA are associated with different intrinsic disease progression pathways manifest at relapse Off-ATRA, and that these different pathways may be short-circuited by ATRA-selectable defects at relapse On-ATRA. ACA and certain PRα/LBD+ were also associated with reduced postrelapse survival.
Research Resource: Whole Transcriptome RNA Sequencing Detects Multiple 1α,25-Dihydroxyvitamin D3-Sensitive Metabolic Pathways in Developing Zebrafish
Craig, Theodore A., Zhang, Yuji , McNulty, Melissa S. , Middha, Sumit , Ketha, Hemamalini , Magis, Andrew T. , Funk, Cory C. , Price, Nathan D. , Ekker, Stephen C. , Kumar, Rajiv , Singh, Ravinder J. , Price, Nathan D , Ekker, Stephen C , Kumar, Rajiv

Mayo Clinic

Molecular Endocrinology | June 27, 2012 | Volume: 26 | Issue: 9 | Pages: 1630-1642

10.1210/me.2012-1113 | PMID 22734042 Get It

AbstractThe biological role of vitamin D receptors (VDR), which are abundantly expressed in developing zebrafish (Danio rerio) as early as 48 h after fertilization, and before the development of a mineralized skeleton and mature intestine and kidney, is unknown. We probed the role of VDR in developing zebrafish biology by examining changes in expression of RNA by whole transcriptome shotgun sequencing (RNA-seq) in fish treated with picomolar concentrations of the VDR ligand and hormonal form of vitamin D3, 1α,25-dihydroxyvitamin D3 [1α,25(OH)2D3)].We observed significant changes in RNAs of transcription factors, leptin, peptide hormones, and RNAs encoding proteins of fatty acid, amino acid, xenobiotic metabolism, receptor-activator of NFκB ligand (RANKL), and calcitonin-like ligand receptor pathways. Early highly restricted, and subsequent massive changes in more than 10% of expressed cellular RNA were observed. At days post fertilization (dpf) 2 [24 h 1α,25(OH)2D3-treatment], only four RNAs were differentially expressed (hormone vs. vehicle). On dpf 4 (72 h treatment), 77 RNAs; on dpf 6 (120 h treatment) 1039 RNAs; and on dpf 7 (144 h treatment), 2407 RNAs were differentially expressed in response to 1α,25(OH)2D3. Fewer RNAs (n = 481) were altered in dpf 7 larvae treated for 24 h with 1α,25(OH)2D3vs. those treated with hormone for 144 h. At dpf 7, in 1α,25(OH)2D3-treated larvae, pharyngeal cartilage was larger and mineralization was greater. Changes in expression of RNAs for transcription factors, peptide hormones, and RNAs encoding proteins integral to fatty acid, amino acid, leptin, calcitonin-like ligand receptor, RANKL, and xenobiotic metabolism pathways, demonstrate heretofore unrecognized mechanisms by which 1α,25(OH)2D3 functions in vivo in developing eukaryotes.
Improvement in Outcomes of Clinical Islet Transplantation: 1999–2010
Barton, Franca B. , Rickels, Michael R. , Alejandro, Rodolfo , Hering, Bernhard J. , Wease, Stephen, Oberholzer, José , Garfinkel, Marc R., Levy, Marlon F. , Pattou, François , Berney, Thierry , Secchi, Antonio , Messinger, Shari , Senior, Peter , Maffi, Paola , Posselt, Andrew M., Stock, Peter G. , Luo, Xunrong , Kandeel, Fouad , Cagliero, Enrico, Turgeon, Nicole A. , Naji, Ali , Greenbaum, Carla J. , Kudva, Yogish C. , Brayman, Kenneth L. , Aull, Meredith J. , Kay, Tom, Fernandez, Luis A. , Vantyghem, Marie‐Christine , Naziruddin, Bashoo , Odorico, Jon S. , Kaufman, Dixon B. , Witkowski, Piotr , O’Connell, Philip J. , Larsen, Christian P. , Bellin, Melena D. , Shapiro, A. M. James , Berney, Thierry , Rickels, Michael R , Messinger, Shari , Pattou, F

Mayo Clinic

Diabetes Care | June 22, 2012 | Volume: 35 | Issue: 7 | Pages: 1436-1445

10.2337/dc12-0063 | PMID 22723582 Get It

OBJECTIVE To describe trends of primary efficacy and safety outcomes of islet transplantation in type 1 diabetes recipients with severe hypoglycemia from the Collaborative Islet Transplant Registry (CITR) from 1999 to 2010. RESEARCH DESIGN AND METHODS A total of 677 islet transplant-alone or islet-after-kidney recipients with type 1 diabetes in the CITR were analyzed for five primary efficacy outcomes and overall safety to identify any differences by early (1999–2002), mid (2003–2006), or recent (2007–2010) transplant era based on annual follow-up to 5 years. RESULTS Insulin independence at 3 years after transplant improved from 27% in the early era (1999–2002, n = 214) to 37% in the mid (2003–2006, n = 255) and to 44% in the most recent era (2007–2010, n = 208; P = 0.006 for years-by-era; P = 0.01 for era alone). C-peptide ≥0.3 ng/mL, indicative of islet graft function, was retained longer in the most recent era (P < 0.001). Reduction of HbA1c and resolution of severe hypoglycemia exhibited enduring long-term effects. Fasting blood glucose stabilization also showed improvements in the most recent era. There were also modest reductions in the occurrence of adverse events. The islet reinfusion rate was lower: 48% by 1 year in 2007–2010 vs. 60–65% in 1999–2006 (P < 0.01). Recipients that ever achieved insulin-independence experienced longer duration of islet graft function (P < 0.001). CONCLUSIONS The CITR shows improvement in primary efficacy and safety outcomes of islet transplantation in recipients who received transplants in 2007–2010 compared with those in 1999–2006, with fewer islet infusions and adverse events per recipient.
Pathology of Acute and Chronic Coronary Stenting in Humans
Farb, Andrew , Sangiorgi, Giuseppe , Walley, Virginia M., Edwards, William D. , Schwartz, Robert S., Carter, Andrew J. , Virmani, Renu

Mayo Clinic

Circulation | June 12, 2012 | Volume: 99 | Issue: 1 | Pages: 44-52

10.1161/01.cir.99.1.44 | PMID 9884378 Get It

Background —Despite the increasing use of stents, few reports have described human coronary artery morphology early and late after stenting. Methods and Results —Histology was performed on 55 stents in 35 coronary vessels (32 native arteries and 3 vein grafts) from 32 patients. The mean duration of stent placement was 39±82 days. Fibrin, platelets, and neutrophils were associated with stent struts ≤11 days after deployment. In stents implanted for ≤3 days, only 3% of struts in contact with fibrous plaque had >20 associated inflammatory cells compared with 44% of struts embedded in a lipid core and 36% of struts in contact with damaged media ( P <0.001). Neointimal growth determined late histological success, and increased neointimal growth correlated with increased stent size relative to the proximal reference lumen area. Neointimal thickness was greater for struts associated with medial damage than struts in contact with plaque ( P <0.0001) or intact media ( P <0.0001). When matched for time since treatment, neointimal cell density in stented arteries was similar to that in unstented arteries that had undergone balloon angioplasty and showed similar proteoglycan deposition. Conclusions —Morphology after coronary stenting demonstrates early thrombus formation and acute inflammation followed by neointimal growth. Medial injury and lipid core penetration by struts result in increased inflammation. Neointima increases as the ratio of stent area to reference lumen area increases. Deployment strategies that reduce medial damage and avoid stent oversizing may lower the frequency of in-stent restenosis.
Guideline for the diagnosis and management of myelofibrosis
Reilly, John T., Beer, Philip , Butt, Nauman M., Conneally, Eibhlin , Duncombe, Andrew , Green, Anthony R. , Michaeel, N. George, Gilleece, Maria , Hall, Georgina , Knapper, Steven , Mead, Adam J. , Sekhar, Mallika , Wilkins, Bridget S., Harrison, Claire , McMullin, Mary Frances , Mesa, Ruben A. , Mead, Adam J , Knapper, Steven

Mayo Clinic

British Journal of Haematology | June 1, 2012 | Volume: 158 | Issue: 4 | Pages: 453-471

10.1111/j.1365-2141.2012.09179.x | PMID 22651893 Get It

Summary The guideline group regarding the diagnosis and management of myelofibrosis was selected to be representative of UK ‐based medical experts, together with a contribution from a single expert from the USA . MEDLINE and EMBASE were searched systematically for publications in E nglish from 1966 until A ugust 2011 using a variety of key words. The writing group produced the draft guideline, which was subsequently revised by consensus of the members of the General Haematology and Haemato‐oncology Task Forces of the British Committee for Standards in Haematology ( BCSH ). The guideline was then reviewed by a sounding board of UK haematologists, the BCSH and the British Society for Haematology Committee and comments incorporated where appropriate. The criteria used to state levels and grades of evidence are as outlined in the Procedure for Guidelines commissioned by the BCSH ; the ‘ GRADE ‘ system was used to score strength and quality of evidence. The objective of this guideline is to provide healthcare professionals with clear guidance on the investigation and management of primary myelofibrosis, as well as post‐polycythaemic myelofibrosis (post‐ PV MF ) and post‐thrombocythemic myelofibrosis (post‐ ET MF ) in both adult and paediatric patients.
The Laboratory‐Clinician Team: A Professional Call to Action to Improve Communication and Collaboration for Optimal Patient Care in Chromosomal Microarray Testing
Wain, Karen E. , Riggs, Erin Rooney , Hanson, Karen , Savage, Melissa, Riethmaier, Darlene, Muirhead, Andrea, Mitchell, Elyse, Packard, Bethanny Smith, Faucett, W. Andrew

Mayo Clinic

Journal of Genetic Counseling | May 17, 2012 | Volume: 21 | Issue: 5 | Pages: 631-637

10.1007/s10897-012-9507-9 | PMID 22610653 Get It

AbstractThe International Standards for Cytogenomic Arrays (ISCA) Consortium is a worldwide collaborative effort dedicated to optimizing patient care by improving the quality of chromosomal microarray testing. The primary effort of the ISCA Consortium has been the development of a database of copy number variants (CNVs) identified during the course of clinical microarray testing. This database is a powerful resource for clinicians, laboratories, and researchers, and can be utilized for a variety of applications, such as facilitating standardized interpretations of certain CNVs across laboratories or providing phenotypic information for counseling purposes when published data is sparse. A recognized limitation to the clinical utility of this database, however, is the quality of clinical information available for each patient. Clinical genetic counselors are uniquely suited to facilitate the communication of this information to the laboratory by virtue of their existing clinical responsibilities, case management skills, and appreciation of the evolving nature of scientific knowledge. We intend to highlight the critical role that genetic counselors play in ensuring optimal patient care through contributing to the clinical utility of the ISCA Consortium's database, as well as the quality of individual patient microarray reports provided by contributing laboratories. Current tools, paper and electronic forms, created to maximize this collaboration are shared. In addition to making a professional commitment to providing complete clinical information, genetic counselors are invited to become ISCA members and to become involved in the discussions and initiatives within the Consortium.
Highly fatal fast-channel syndrome caused by AChR ɛ subunit mutation at the agonist binding site
Shen, Xin‐Ming , Brengman, Joan M., Edvardson, Simon , Sine, Steve M., Engel, Andrew G. , Sine, Steven M.

Mayo Clinic

Neurology | May 17, 2012 | Volume: 79 | Issue: 5 | Pages: 449-454

10.1212/wnl.0b013e31825b5bda | PMID 22592360 Get It

Temporal Trends in Incidence of Kidney Stones Among Children: A 25-Year Population Based Study
Dwyer, Moira , Krambeck, Amy E. , Bergstralh, Eric J., Milliner, Dawn S. , Lieske, John C. , Rule, Andrew D.

Mayo Clinic

Journal of Urology | May 15, 2012 | Volume: 188 | Issue: 1 | Pages: 247-252

10.1016/j.juro.2012.03.021 | PMID 22595060 Get It

Are MuSK antibodies the primary cause of myasthenic symptoms?
Selcen, Duygu , Fukuda, Taku , Shen, Xin‐Ming , Engel, Andrew G.

Mayo Clinic

Neurology | May 14, 2012 | Volume: 62 | Issue: 11 | Pages: 1945-1950

10.1212/01.wnl.0000128048.23930.1d | PMID 15184594 Get It